This study is for men with high-risk prostate cancer, which is when cancer in the prostate gland is more likely to grow or spread. The study looks at two types of treatments: less intense and more intense. It uses a special test called a gene risk score to decide which treatment is best. For men with a low gene risk score, the study tests if a shorter treatment with hormone therapy (reducing male hormones that help cancer grow) and radiation (high-energy rays to kill cancer cells) works as well as the usual longer treatment. For men with a high gene risk score, the study adds another medicine called apalutamide, which stops cancer from using male hormones, to the usual treatment to see if it helps keep the cancer from spreading longer.

• The study involves regular visits and tests over a period up to 24 months.
• Participants receive either 12 or 24 months of treatment, with some taking additional medication.
• Potential side effects and risks will be monitored throughout the study.